QiYi Health Files IPO Prospectus After Being Named Twice in 'Future Healthcare 100' Within Two Years

On June 15, 2022, the “2022 Top 100 Future Healthcare Companies Main List” was officially released. As an outstanding representative of digital therapeutics,Qiyi Medical Ranks Among China’s Top 100 Innovative Digital Health Companies and the Value Sector List. This marks Qiyi Medical’s second inclusion, following its selection for the “Top 100 Future Healthcare Companies” list in 2021. Furthermore, VCBeat’s “2022 Digital Therapeutics Industry Research Report” also featured Qiyi Medical as a leading enterprise case study in the respiratory field.

Qiyi Medical is a healthcare technology company grounded in real-world study data, specializing in the full-course management of respiratory diseases and the development of digital diagnostic and therapeutic products.In the selection of the main list for the Top 100 Future Healthcare Companies, key evaluation criteria include the market size of the industry in which the company operates, the company’s growth potential, and the innovativeness and breakthrough nature of its technologies and products.

Qiyi Medical, established two years ago, has connected with over 7,000 medical institutions across China, accumulated data on nearly 10 million patients, and built the world’s largest database for innovative management models of respiratory diseases.

The company continues to deepen its presence in the respiratory care sector while expanding horizontally into related digital therapeutics products, thereby enriching its product portfolio and positioning itself as a leading enterprise with the most comprehensive range of digital therapeutics offerings in the respiratory field of the healthcare industry.

To date, Qiyi Medical has conducted several multicenter prospective clinical trials, including “A Multicenter Study on Optimizing the COPD Screening Questionnaire Based on Machine Learning and Evaluating Its Effectiveness for COPD Screening in China,” “Research on an Early Warning Model for Acute Exacerbations in COPD Patients Based on the Internet of Things and Artificial Intelligence,” and “Study on the Efficacy of Music Therapy for Remote Rehabilitation in COPD Patients.”Five digital therapeutics have entered stages such as pipeline R&D and registration for certification, with market launches expected to commence in 2023.。

Qiyi Medical is a senior member of the Digital Therapeutics Alliance (DTA), a standing committee member of the China Association for Medical Devices Industry, and a member unit of the Professional Committee on Digital Therapeutics Systems Engineering. Qiyi Medical has secured investments from renowned institutions such as Matrix Partners China, Yuanhe Yuandian, and Shijie Venture Capital.

Development Trajectory of Qiyi Medical

Song Siyi, Founder and CEO of Qiyi MedicalWith over 20 years of experience in Fortune 500 companies and the industry. As a digital health technology company, Qiyi Medical’s digital therapeutics products are primarily driven by integrated software and hardware solutions, with a focused commitment to leading the development of digital therapeutics and establishing industry standards in the respiratory care sector.

“Against the backdrop of the global COVID-19 pandemic, attention to respiratory diseases has reached an unprecedented level across the entire healthcare system, from national and local governments to health institutions at all levels, hospitals, and professional societies. Favorable capital investment, along with R&D spending on new drugs and innovative medical devices, is fueling the robust growth of the respiratory disease management market and spurring various innovative models, with digital therapeutics serving as our key focus,” said Ms. Song Siyi.

In contrast, digital therapeutics have already gained significant momentum in Europe and the United States. Amid this prevailing trend, Qiyi Medical aims to capture market share, emerge as a domestic leader in digital therapeutics, and demonstrate “Qiyi Speed” to the industry.

QiYi Medical’s overarching rationale for developing digital therapeutics (DTx) products is to directly address patients’ pain points while prioritizing their psychological and physiological acceptance, thereby delivering a positive treatment experience. The respiratory rehabilitation DTx product currently under development by QiYi Medical engages patients through a scientific approach that integrates hardware and software with activities popular among middle-aged and older adults—such as music and exercise—seamlessly incorporating them into daily life to enhance adherence.

In addition to its COPD rehabilitation products, Qiyi Medical’s product pipeline under development also covers scenarios such as disease screening and early warning of acute exacerbations.

Qiyi Medical has established a comprehensive, multi-channel ecosystem encompassing government entities, hospitals, pharmaceutical companies, commercial insurers, and patients. Through initiatives such as specialty development and city-wide implementation models, the company has achieved end-to-end management of chronic obstructive pulmonary disease (COPD) and integrated data flows across in-hospital and out-of-hospital settings.

On one hand, Qiyi Medical has collaborated with academicians and respiratory specialists to establish a standardized, full-cycle management model for chronic obstructive pulmonary disease (COPD) at the provincial and municipal levels, providing comprehensive digital management services—including screening, diagnosis, treatment, and follow-up—for key populations in regions such as Henan and Zhejiang.

On the other hand, Qiyi Medical collaborated with the foundation to launch the "Full-Course Management of Chronic Respiratory Diseases" project, deploying pre-diagnostic assessment systems for respiratory diseases in 1,700 hospitals across China. The project has provided screening and follow-up services for high-prevalence respiratory conditions, including chronic obstructive pulmonary disease (COPD), asthma, and lung cancer, to over 5 million patient visits, laying a solid foundation for the subsequent integration of digital therapeutic products.

Therefore, unlike the singular business models of other early chronic disease management companies, Qiyi Respiratory’s digital therapeutics for chronic diseases—supported by its robust pipeline and leveraging the “province/city-wide model” in collaboration with regional medical consortia—has already established strong capabilities in vertical disease-specific channel integration and a closed-loop commercial system covering the entire disease management journey.

Leveraging its core strengths, Qiyi Medical has achieved comprehensive omni-channel coverage in the field of respiratory diseases, spanning both online and offline platforms as well as in-hospital and out-of-hospital settings. The company is engaged in multiple clinical research collaborations with leading industry experts, focusing on generating robust clinical evidence to help establish industry standards for digital therapeutics and drive sector development.

Qiyi Medical is firmly optimistic about the development and prospects of digital therapeutics in China and worldwide. As a member of the DTA, Qiyi Medical will establish its foundation in China while expanding globally, aiming to introduce a richer array of high-quality digital therapeutic products to broader markets and deliver health benefits to more patients with chronic respiratory diseases.

According to VCBeat’s “2022 Digital Therapeutics Industry Research Report,” digital therapeutics for respiratory diseases rank third in terms of the total number of FDA-approved products. Leading companies have already established extensive commercial footprints and achieved stable revenue streams. Thus, drawing on the development of this sector abroad, digital therapeutics for respiratory disease management demonstrate substantial clinical value, which has been validated through real-world applications, indicating promising prospects.